Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

medifast inc. - MED

MED

Close Chg Chg %
11.83 0.55 4.65%

Closed Market

12.38

+0.55 (4.65%)

Volume: 564.88K

Last Updated:

Dec 12, 2025, 3:59 PM EDT

Trade Now

Company Overview: medifast inc. - MED

MED Key Data

Open

$11.74

 Day Range

11.74 - 12.47

52 Week Range

10.36 - 20.58

 Market Cap

$128.16M

Shares Outstanding

10.99M

 Public Float

10.63M

Beta

0.50

 Rev. Per Employee

N/A

P/E Ratio

566.03

 EPS

$0.02

Yield

0.00%

 Dividend

$1.65

EX-DIVIDEND DATE

Sep 18, 2023

 SHORT INTEREST

N/A

AVERAGE VOLUME

232.25K

  

MED Performance

1 Week
 
 13.60%
 
1 Month
 
 8.61%
 
3 Months
 
 -11.52%
 
1 Year
 
 -35.49%
 
5 Years
 
 -93.83%
 

MED Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About medifast inc. - MED

Medifast, Inc. is a health and wellness company, which engages in the provision of habit-based and coach-guided lifestyle solutions called OPTAVIA. It offers and ships OPTAVIA products directly to its customers. It focuses on coaching healthy habits through a health transformational system. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.

MED At a Glance

Medifast, Inc.
100 International Drive
Baltimore, Maryland 21202
Phone 1-410-581-8042 Revenue 602.46M
Industry Miscellaneous Commercial Services Net Income 2.09M
Sector Commercial Services Employees 504
Fiscal Year-end 12 / 2025
View SEC Filings

MED Valuation

P/E Current 566.029
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 92.396
Price to Sales Ratio 0.321
Price to Book Ratio 0.917
Price to Cash Flow Ratio 7.89
Enterprise Value to EBITDA 2.315
Enterprise Value to Sales 0.078
Total Debt to Enterprise Value 0.343

MED Efficiency

Revenue/Employee 1,195,363.095
Income Per Employee 4,148.81
Receivables Turnover N/A
Total Asset Turnover 1.945

MED Liquidity

Current Ratio 3.342
Quick Ratio 2.68
Cash Ratio 2.53

MED Profitability

Gross Margin 73.801
Operating Margin 0.478
Pretax Margin 0.629
Net Margin 0.347
Return on Assets 0.675
Return on Equity 1.016
Return on Total Capital 0.924
Return on Invested Capital 0.956

MED Capital Structure

Total Debt to Total Equity 7.675
Total Debt to Total Capital 7.128
Total Debt to Total Assets 5.499
Long-Term Debt to Equity 4.732
Long-Term Debt to Total Capital 4.395
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medifast Inc. - MED

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.53B 1.60B 1.07B 602.46M
Sales Growth
+63.25% +4.75% -32.94% -43.80%
Cost of Goods Sold (COGS) incl D&A
398.49M 445.96M 296.20M 157.84M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
11.88M 17.08M 17.71M 17.40M
Depreciation
10.77M 14.00M 14.61M 17.40M
Amortization of Intangibles
- 1.11M 3.08M 3.11M
COGS Growth
+68.12% +11.91% -33.58% -46.71%
Gross Income
1.13B 1.15B 775.85M 444.62M
Gross Income Growth
+61.59% +2.22% -32.69% -42.69%
Gross Profit Margin
+73.89% +72.10% +72.37% +73.80%
2021 2022 2023 2024 5-year trend
SG&A Expense
911.36M 936.61M 649.45M 441.75M
Research & Development
4.40M 4.50M 4.60M 4.60M
Other SG&A
906.96M 932.11M 644.85M 437.14M
SGA Growth
+61.69% +2.77% -30.66% -31.98%
Other Operating Expense
- - - -
-
Unusual Expense
- - 31.20M 4.09M
-
EBIT after Unusual Expense
216.24M 184.81M 126.40M (1.21M)
Non Operating Income/Expense
119.00K (46.00K) 2.40M 5.00M
Non-Operating Interest Income
- - 2.49M 4.80M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 231.00K 701.00K
-
Interest Expense Growth
- - +203.46% -100.00%
-
Gross Interest Expense
- - 231.00K 701.00K
-
Interest Capitalized
- - - -
-
Pretax Income
216.13M 184.06M 128.80M 3.79M
Pretax Income Growth
+60.97% -14.84% -30.02% -97.06%
Pretax Margin
+14.16% +11.51% +12.01% +0.63%
Income Tax
52.10M 40.49M 29.38M 1.70M
Income Tax - Current - Domestic
55.81M 41.41M 28.17M 9.10M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(3.71M) (924.00K) 1.21M (7.40M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
164.03M 143.57M 99.42M 2.09M
Minority Interest Expense
- - - -
-
Net Income
164.03M 143.57M 99.42M 2.09M
Net Income Growth
+59.47% -12.48% -30.75% -97.90%
Net Margin Growth
+10.75% +8.98% +9.27% +0.35%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
164.03M 143.57M 99.42M 2.09M
Preferred Dividends
- - - -
-
Net Income Available to Common
164.03M 143.57M 99.42M 2.09M
EPS (Basic)
14.0138 12.8243 9.134 0.1913
EPS (Basic) Growth
+60.37% -8.49% -28.78% -97.91%
Basic Shares Outstanding
11.71M 11.20M 10.88M 10.93M
EPS (Diluted)
13.8856 12.7322 9.1031 0.1907
EPS (Diluted) Growth
+59.97% -8.31% -28.50% -97.91%
Diluted Shares Outstanding
11.81M 11.28M 10.92M 10.96M
EBITDA
228.12M 233.08M 144.12M 20.28M
EBITDA Growth
+61.30% +2.18% -38.17% -85.93%
EBITDA Margin
+14.95% +14.58% +13.44% +3.37%

Snapshot

Average Recommendation HOLD Average Target Price 15.00
Number of Ratings 1 Current Quarters Estimate -0.82
FY Report Date 12 / 2025 Current Year's Estimate -1.12
Last Quarter’s Earnings -0.21 Median PE on CY Estimate N/A
Year Ago Earnings 1.84 Next Fiscal Year Estimate -1.61
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.82 -0.36 -1.12 -1.61
High Estimates -0.82 -0.36 -1.12 -1.61
Low Estimate -0.82 -0.36 -1.12 -1.61
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Medifast Inc. - MED

Date Name Shares Transaction Value
Mar 28, 2025 Daniel R. Chard Chairman & CEO; Director 176,246 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 28, 2025 James P. Maloney Chief Financial Officer 42,299 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 28, 2025 Jonathan B. MacKenzie VP, Finance & CAO 11,138 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Daniel R. Chard Chairman & CEO; Director 53,157 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.94 per share 741,008.58
Mar 21, 2025 Daniel R. Chard Chairman & CEO; Director 51,293 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.35 per share 736,054.55
Mar 21, 2025 James P. Maloney Chief Financial Officer 18,576 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.94 per share 258,949.44
Mar 21, 2025 James P. Maloney Chief Financial Officer 18,138 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.35 per share 260,280.30
Mar 21, 2025 Jonathan B. MacKenzie VP, Finance & CAO 3,566 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.94 per share 49,710.04
Mar 21, 2025 Jonathan B. MacKenzie VP, Finance & CAO 3,467 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.35 per share 49,751.45

Medifast Inc. in the News